NextCure, LegoChem Biosciences Ink Collaborative Pact For Antibody Drug Conjugates

  • NextCure Inc NXTC and LegoChem Biosciences Inc announced a collaboration and co-development agreement to generate a B7-H4 antibody-drug conjugate (ADC) and options for two additional targets. 
  • The B7-H4 ADC will utilize NextCure's B7-H4 antibody and LCB's ConjuAllTM ADC technology.
  • Under the terms of the agreement, both parties will equally share the costs to develop the molecules and profits on commercialized products. 
  • Related: NextCure Launches Early-Stage Study For NC762 In Solid Tumor Settings.
  • The parties will utilize their respective product development capabilities to generate the B7-H4 ADC and advance it to the clinic. 
  • In addition, there are options for the parties to nominate two additional targets for ADC development beyond B7-H4.
  • "We are excited to work with LCB and apply ConjuAllTM, a leading ADC technology, to add a new treatment modality to our B7-H4 program," said Timothy Mayer, NextCure's Chief Operating Officer.
  • Price Action: NXTC shares closed lower by 1.78% at $1.66 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareContractsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!